Boundless Bio, Inc. (BOLD) stock
BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.40−0.01 (-0.41%)
Close on Nov 18, 2026Market cap $54.60MP/E –Yield –
Boundless Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Boundless Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$56.73M. For fiscal 2025 it was -$47.21M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$47.21M | – |
| FY2024 | Dec 31, 2024 | -$63.38M | – |
| FY2023 | Dec 31, 2023 | -$47.49M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$21.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.98M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.21M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.88M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.75M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.95M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.18M | – |
See a number that looks wrong?